

Claris Lifesciences Limited

Regd. Office: Claris Corporate Headquarters, Nr. Parimal Railway Crossing, Ellisbridge, Ahmedabad – 380006
 website : www.clarislifesciences.com, e-mail : investorservices.corp@clarislifesciences.com , CIN : L85110GJ1994PLC022543

Unaudited Financial Results for the Quarter ended March 31, 2014

(Rs. In Lacs except EPS and Shares)

Particulars	Consolidated				Standalone			
	Quarter Ended		Year ended		Quarter Ended		Year ended	
	31st Mar 2014	31st Dec 2013	31st Mar 2013	31st Dec 2013	31st Mar 2014	31st Dec 2013	31st Mar 2013	31st Dec 2013
	Unaudited	Unaudited	Unaudited	Audited	Unaudited	Unaudited	Unaudited	Audited
PART II								
A PARTICULARS OF SHAREHOLDING								
1. Public Shareholding								
- No. of shares	25,392,554	25,392,554	24,212,434	25,392,554	25,392,554	25,392,554	24,212,434	25,392,554
- Percentage of shareholding	39.79	39.79	37.94	39.79	39.79	39.79	37.94	39.79
2. Promoters and Promoter group shareholding								
a) Pledged/Encumbered								
- Number of shares	6,844,532	-	7,724,000	-	6,844,532	-	7,724,000	-
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	17.81	-	19.50	-	17.81	-	19.50	-
- Percentage of shares (as a% of the total share capital of the Company)	10.73	-	12.10	-	10.73	-	12.10	-
b) Non-encumbered								
- Number of Shares	31,580,679	38,425,211	31,881,331	38,425,211	31,580,679	38,425,211	31,881,331	38,425,211
- Percentage of shares (as a% of the total shareholding of promoter and promoter group)	82.19	100.00	80.50	100.00	82.19	100.00	80.50	100.00
- Percentage of shares (as a % of the total share capital of the Company)	49.49	60.21	49.96	60.21	49.49	60.21	49.96	60.21
B INVESTOR COMPLAINTS								
Pending at the beginning of the quarter					Nil			
Received during the quarter					3			
Disposed of during the quarter					3			
Remaining unresolved at the end of the quarter					Nil			

Notes:

- 1 The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 9th May, 2014
- 2 The Company has only one reportable business segment, namely, Drugs & Pharmaceuticals.
- 3 On 31st July 2013, pursuant to agreements with Otsuka Pharmaceutical Factory, Inc., Japan (Otsuka) and Mitsui & Co. Ltd., Japan (Mitsui), the Company has transferred its Infusion Business to Claris Otsuka Limited on a slump sale basis. Post transfer of business, the Company holds 20% of equity share capital of Claris Otsuka Limited
- Necessary disclosures pertaining to the discontinuing operations and re-organisation of the business, as per the requirements of Accounting Standard – 24 (AS-24) “Discontinuing Operations” are as under: -

(Rs. In Lacs)

Particulars	-----Consolidated and Standalone Results-----			
	Quarter Ended		Year Ended	
	31st March 2014	31st December 2013	31st March 2013	31st December 2013
Revenue	-	-	8,235.00	22,055.73
Profit / (Loss) Before Tax	-	-	1,104.66	2,958.61
Profit / (Loss) After Tax	-	-	774.41	2,074.10

In view of the transfer of the infusion business on 31st July, 2013, the figures for the quarters ended on 31st March 2014 and on 31st December 2013 do not include corresponding figures pertaining to the discontinued operations for respective periods and hence, to that extent, the same are not comparable with the figures for the previous corresponding periods / year.

- 4 The figures for the previous year / period have been regrouped / rearranged wherever necessary.

For Claris Lifesciences Limited

Place : Ahmedabad
Date 9th May , 2014

Arjun Handa
Managing Director & CEO